Uterine Neoplasm

Phase II trial of AKT-inhibitor capivasertib in patients with solid tumors and AKT1/2/3 alterations. One patient with an AKT1 L52R mutant endometrioid cancer achieved partial response that lasted for … (full text at CIViC)

PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC

Extension and reduction of the ATR exon 10 A10 repeat (alters codon I774) was associated with poorer overall and disease-free survival in patients with endometrioid endometrial cancer when compared to… (full text at CIViC)

PMID 19470935 · Zighelboim et al., 2009 · Open in CIViC

In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol.

PMID 12559175 · Anand et al., 2003 · Open in CIViC

In the uterine carcinoma cohort of the phase II TAPUR trial (NCT02693535), PRs were observed in 3 of 15 evaluable patients with BRCA1 (n = 2) or BRCA2 (n = 1) alterations, with response durations of 8… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines e… (full text at CIViC)

PMID 23415752 · Stordal et al., 2013 · Open in CIViC

Analysis of 5 uterine serous carcinoma (USC) primary cell lines in vitro indicated enhanced sensitivity to CDK2/9 inhibitor CYC065 in cell lines overexpressing cyclin E1 (CCNE1) in comparison to low C… (full text at CIViC)

PMID 27351214 · Cocco et al., 2016 · Open in CIViC

In endometrial carcinoma (EMCA) preclinical models, CCNE1 amplification predicted synergistic sensitivity to lunresertib (RP-6306) + camonsertib (RP-3500), with ~80% growth inhibition at low-dose comb… (full text at CIViC)

PMID 40169546 · Xu et al., 2025 · Open in CIViC

In a clinical trial including 21 patients, CD44v6 expression (prior to and after to NAC) is a predictive factor of response to NAC by multivariate analysis (p = 0.0099 and p = 0.0470). Moreover, CD44v… (full text at CIViC)

PMID 11136572 · Costa et al., 2001 · Open in CIViC

A 62 year old nonsmoker with KRAS and ERBB family wild-type metastatic pulmonary adenocarcinoma was found to have a CD74-NRG1 fusion. The patient achieved a durable response when treated with afatinib… (full text at CIViC)

PMID 28502724 · Gay et al., 2017 · Open in CIViC

A single case of pulmonary mucinous adenocarcinoma in a 62 year old patient was found to have a CD74-NRG1 fusion. Afatinib treatment resulted in symptomatic and radiographic response for 26 weeks, at … (full text at CIViC)

PMID 29169524 · Cheema et al., 2017 · Open in CIViC

COL1A1::PDGFB fusion is typically found in dermatofibrosarcoma protuberans, but this study revealed it could appear in uterine sarcoma, and the presence of this fusion was suggested as a feature for a… (full text at CIViC)

PMID 30877273 · Croce et al., 2019 · Open in CIViC

In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival.

PMID 21730982 · Iida et al., 2011 · Open in CIViC

A 33-year-old Han Chinese woman has been associated with an NTRK fusion cervical sarcoma which was positive for Pan-TRK by immunohistochemistry (IHC) analysis. However, FISH for NTRK1 was negative. Th… (full text at CIViC)

PMID 35572973 · Dang et al., 2022 · Open in CIViC

In a preclinical study of uterine cancer cell lines resistant to EphA2 inhibitors (HEC-1A, Ishikawa, RL-95), EphA2-positive cells treated with the MEK inhibitor trametinib restored sensitivity to dasa… (full text at CIViC)

PMID 34391578 · Wu et al., 2021 · Open in CIViC

In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient… (full text at CIViC)

PMID 15746676 · Santin et al., 2005 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the … (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In a randomized phase 2 trial, patients who have uterine serous carcinoma that overexpress erbb2 were allocated carboplatin-paclitaxed with or without trastuzumab. Median progression-free survival was… (full text at CIViC)

PMID 29584549 · Fader et al., 2018 · Open in CIViC

In uterine tumors resembling ovarian sex cord tumor (UTROSCT; n = 4), RNA sequencing identified recurrent ESR1::NCOA3 (n = 2), ESR1::NCOA2 (n = 1), and GREB1::NCOA2 (n = 1) fusions, involving NCOA2/3 … (full text at CIViC)

PMID 30273195 · Dickson et al., 2019 · Open in CIViC

In a retrospective UTROSCT cohort (n = 17, follow-up n = 13), 3 patients (23.1%) carrying GREB1::NCOA2, ESR1::NCOA3 or ESR1::CITED2 fusions developed pelvic, abdominal or pulmonary recurrence, with re… (full text at CIViC)

PMID 38000680 · Qijun et al., 2024 · Open in CIViC

Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC)

PMID 26324363 · Tabernero et al., 2015 · Open in CIViC

patients with FGFR2 mutations had a much higher incidence of progression (32/125, 26%) whereas among those with wild type where only (120/848,14%) displayed incidences of progression. The mutated FGFR… (full text at CIViC)

PMID 28314589 · Jeske et al., 2017 · Open in CIViC

Treatment of cell lines harboring FGFR2 mutations with dovitinib 0.5 mmol/L for 72 hours resulted in a significant decrease in cell viability of AN3CA (37.80%) and MFE-296 (53.14%). Conversely, in cel… (full text at CIViC)

PMID 24448819 · Eritja et al., 2014 · Open in CIViC

The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wi… (full text at CIViC)

PMID 18757403 · Byron et al., 2008 · Open in CIViC

A study that aims to analyse the biological significance of the FGFR3-TACC3 fusion. They transfected the K508M (also referred to as KD or kinase-dead) FGFR3-TACC3 fusion transcript into cervical epith… (full text at CIViC)

PMID 29358619 · Tamura et al., 2018 · Open in CIViC

Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

This paper details a prospective single-arm personalized cancer therapy study with n = 16 patients. The disease type was peritoneal mucinous carcinomatosis, predominantly of appendiceal origin. Palboc… (full text at CIViC)

PMID 39413348 · Weitz et al., 2025 · Open in CIViC

Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild-type (N=6; not reached; p < 0.… (full text at CIViC)

PMID 27154293 · Pietrantonio et al., 2016 · Open in CIViC

Fresh tumor tissue 291 cervical cancer patients was fresh frozen at -70 degrees. DNA from samples was purified and analyzed via PCR for HPV 16, 18, and 6. HPV was found in 247 (85%) of tumors. HPV-16 … (full text at CIViC)

PMID 8827013 · Burger et al., 1996 · Open in CIViC

Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT).

PMID 18607592 · Kalender et al., 2009 · Open in CIViC

Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment… (full text at CIViC)

PMID 16487996 · Salvatierra et al., 2006 · Open in CIViC

In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplifica… (full text at CIViC)

PMID 23099803 · Birkeland et al., 2012 · Open in CIViC

40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRA… (full text at CIViC)

PMID 27502722 · Pietrantonio et al., 2016 · Open in CIViC

94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tum… (full text at CIViC)

PMID 24166148 · Mackay et al., 2014 · Open in CIViC

A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC)

PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC

MLH1 E13fs (c.37del), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 46 year old female patient (sLS-1) with suspected Lynch Syndrome (LS). The pa… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

MLH1 G606fs*2 (c.1816_1817del), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 46 year old female patient (sLS-1) with suspected Lynch Syndrome (L… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This variant (M490T), identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient was… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673. Loss of MRE11 was identified in 30.7% o… (full text at CIViC)

PMID 24927325 · Koppensteiner et al., 2014 · Open in CIViC

MSH2 E483G (c.1448A > G), identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a 69 year old female patient (sLS-39) with suspected Lynch Syndrome (LS). Th… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This variant (R383*), identified in two patients, was confirmed to be a somatic mutation in both patients' microsatellite-unstable tumors (39 year-old female with endometrial cancer & 34 year-old fema… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

This variant (V352I), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient wa… (full text at CIViC)

PMID 25111426 · Geurts-Giele et al., 2014 · Open in CIViC

A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC)

PMID 36972026 · Mirza et al., 2023 · Open in CIViC

A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC)

PMID 38866180 · Powell et al., 2024 · Open in CIViC

Authors tested various cervical cancer cell lines (CaSki, SiHa and HeLa) for their responses to cisplatin, radiation therapy, and GDC-0941. CaSki cells that are heterozygous for the PIK3CA-E545K mutat… (full text at CIViC)

PMID 27489350 · Arjumand et al., 2016 · Open in CIViC